Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen, Mitsubishi Pharma do Schizophrenia Drug Deal

NEW YORK, Nov. 5-CuraGen will use its functional genomics techniques to validate and characterize drug targets for schizophrenia for Mitsubishi Pharma Corporation, the two companies said today.


CuraGen will retain ownership of new protein therapeutics, antibody drugs and small molecule targets discovered in this partnership. MPC will also provide the company with undisclosed financial support.


SC Biosciences, CuraGen's Japanese agent, helped execute this deal.


For more information, see the press release.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.